peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Event

Investors

OMX Stockholm

( %)
HNSA  SEK

Annual Report 2023
Sustainability Report 2023

Addressing unmet need
in rare diseases

Read the reports

Hansa Biopharma in brief

We are leveraging our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.

From imlifidase, we have developed a first-in-class therapy to enable kidney transplantation in highly sensitized patients. The European Commission has conditionally authorized our first product for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

Our research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and with operations in other European countries and in the U.S.

Our Equity story

Learn more

Targeting rare diseases with a high unmet medical needs

Commercializing the first authorized product in first markets and indications

Evolving into a fully integrated biopharmaceutical company

Leveraging our proprietary antibody cleaving enzyme technology

green vials
Calendar

Upcoming events

27
Jun

Annual General Meeting

18
Jul

Half-year Report January-June 2024

09
Sep

H.C. Wainwright 26th Annual Global Investment Conference, New York

View all events
Latest Financial Results

Interim report January-March 2024

View all results

Press releases

Our latest press releases

Upcoming

Achieved and upcoming milestones

 2023 Q4 - Achieved
  • HNSA-5487 (Lead NiceR candidate): High-level data readout from Phase 1
  • Long-term follow-up (Kidney tx): 5-year data readout
  • GBS Phase 2: First data readout
  • AMR Phase 2: Full data readout
  • Sarepta DMD pre-treatment Phase 1b: Commence clinical study
 2024
  • GBS Phase 2: Outcome of comparative efficacy analysis
  • Genethon Crigler-Najjar Phase 1/2: Initiate clinical study with imlifidase prior to GNT-0003 
  • HNSA-5487 (Lead NiceR candidate): Further analysis around endpoints to be completed in 2024 incl. lead indication
  • U.S. ConfIdeS (Kidney tx) Phase 3: Complete randomization
  • Sarepta imlifidase in phase 1b in DMD: First high level data read-out from phase 1b

2025
  • U.S. ConfIdeS (Kidney tx) Phase 3: BLA submission
  • Anti-GBM disease Phase 3: Complete enrolment
Coffee and notepad

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.
Investor relations

Evan Ballantyne

Chief Financial Officer

Email: IR@hansabiopharma.com